Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 3/20 | 0.40 |
| ▸ | BCDIN3D | Q7Z5W3 | 2/20 | 0.32 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | RET | P07949 | 1/20 | 0.30 |
| ▸ | KIF5B | P33176 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | FLT3 | P36888 | 1/20 | 0.30 |
| ▸ | CCDC6 | Q16204 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25875863 | 0.88 | PDE2A (0.41) | PDE2ABCDIN3DSHMT2RAB9ASMN1; SMN2 | |
| SCHEMBL25876132 | 0.88 | PIK3CA (0.34) | PIK3CA | |
| SCHEMBL25876239 | 0.87 | MAT2A (0.32) | PDE2ASMN1; SMN2KMT2A | |
| SCHEMBL25876280 | 0.87 | PDE1A (0.37) | SMN1; SMN2PDE4BKMT2A | |
| SCHEMBL25875946 | 0.86 | MAT2A (0.40) | SMN1; SMN2PIK3CAPDE4BKMT2A | |
| SCHEMBL25876042 | 0.86 | MAT2A (0.33) | SMN1; SMN2KMT2A | |
| SCHEMBL25876260 | 0.85 | PIK3CA (0.36) | PIK3CA | |
| SCHEMBL25876083 | 0.85 | MERTK (0.35) | — | |
| SCHEMBL25876052 | 0.84 | PDE9A (0.34) | JAK2RETKIF5BKDRFLT3 | |
| SCHEMBL25876309 | 0.83 | PIK3CA (0.36) | PDE2APIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234954-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | TYK MEDICINES, INC. (CN) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234954-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | RET, ROR1, FGFR3 | PDE2A 1000/4885BCDIN3D 856/4885SHMT2 2855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.